New intramuscular administration for Biogen's MS therapy Plegridy approved in the EU

New intramuscular administration for Biogen's MS therapy Plegridy approved in the EU

Publication date: Jan 07, 2021

The European Commission (EC) has approved a new intramuscular (IM) injection route of administration for Biogen’s Plegridy for the treatment of relapsing-remitting multiple sclerosis (RRMS).

The new IM route of administration, while still providing patients with the same efficacy and safety of Plegridy, has the potential for reduction in injection site reactions compared to SC administration, Biogen said in a statement.

Aside from MS, Biogen has high hopes for its potential Alzheimer’s disease therapy aducanumab, which is currently under review with the US Food and Drug Administration.

Concepts Keywords
Active Ingredient MS
Avonex Oral therapy
Biogen Life sciences
Central Nervous System Cytokines
District Biology
European Commission Drugs
FDA Multiple sclerosis
Federal Circuit Spinal muscular atrophy
High Hopes Biogen
IM Interferon beta-1a
Interferon Beta 1a Monoclonal antibodies
Interferons Peginterferon beta-1a
Intramuscular PEGylation
Intramuscular Administration Aducanumab
Multiple Sclerosis
Mylan
Patent
Pegylated
Subcutaneous

Semantics

Type Source Name
drug DRUGBANK Aducanumab
drug DRUGBANK Dimethyl fumarate
drug DRUGBANK Aspartame
disease MESH injection site reactions
disease MESH relapsing-remitting multiple sclerosis
drug DRUGBANK Peginterferon beta-1a
drug DRUGBANK Interferon beta-1a

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *